CSE:NOVOB.CO

Novo Nordisk stock slips again as Wegovy price cuts and CagriSema doubts weigh
····

Novo Nordisk stock slips again as Wegovy price cuts and CagriSema doubts weigh

Novo Nordisk shares fell 1.7% in Copenhagen after the company announced U.S. list-price cuts for Wegovy and Ozempic starting January 2027. Analysts flagged rising price pressure and doubts over Novo’s next obesity drug, CagriSema, which underperformed Eli Lilly’s rival in trials. Barclays slashed its peak sales forecast for CagriSema to $2 billion from $12 billion. Novo has lost about $475 billion in market value since June.
February 25, 2026

Stock Market Today

  • Temple & Webster (ASX:TPW) Shares Fall 75%: Is It a Buy Amidst Market Challenges?
    May 26, 2026, 7:58 PM EDT. Temple & Webster Group Ltd (ASX:TPW) shares have plunged roughly 75% over 12 months due to slowed housing demand, rising costs, and consumer tightening. Despite a recent 19.8% revenue rise, profits tumbled 36%, and gross margins slipped from 32.4% to 30.5%, impacted by high customer acquisition costs and expansion efforts. The company's post-earnings 25% share drop highlights investor concerns. However, a May 2026 trading update showed improved profitability after strategic adjustments. Incoming CEO Susie Sugden's marketing expertise may steer growth amid ongoing challenges. Temple & Webster remains a speculative buy for patient investors seeking long-term gains from the growing Australian furniture market, despite near-term volatility.